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Summary
In this thesis, the eÍïect of potassium channelrnodulatrng agents on insulin
secretron and insulin sensitrvity has been investigated. Studies were
perÍbrmed in healthy volunteers, in patients with essential hyper-tension,
whrch is associated with rnsulin resistance and hyperinsulinemia, in patients
with non-insulin-dependent diabetes mellitus, a condition that cornbines
resistance to insulin and a defèct rn insulin secretion by the pancreatic B cell,
and in patients with hypokalernic penodic paralysis, a disease in which
abnormalitres in insulin release may be involved. Tlris summary atternpts
to answer the questions, that are put fbrward in the introductron.
In chapter I tl ie clinical role of the ATP-sensitive potassium channels
is reviewed. Knowledge aborrt he K.[ATP] channels has prown in the past
decade, due to techniques fbr their assessrnent (isotope f'lux studres and the
voltage-clamp technique), and the development of dr-ugs that can either
open or close these cell rnembrane stmctures. These K-[Al-p] channel
opening- and closing dmgs and therr (possible) el fects on insulrn release
and rnsulin sensitivity are discussed. K*[ATP] channel opening drugs are
effèctive rn lowering blood pressure and in the rnanagernent of ischemic
heart disease. 1'hey are as effective in achieving adequate blood pressure
control as calcium channel blockers The possibility is drscussed, that these
agents cor,rld iurinish insLrhn release in vivo by opening pancreatrc B cell
K-[ATP] channels, an eÍfect fbmerly described in in vitro stuclies. K*IATp]
channel blocking drugs, better known as sulphonylurea denvatives (SU),
are used Íbr the rnanagement of NIDDM. They enhance insulin release in
NIDDM patrents, irnproving rnetabolic control. The hypothesis, that SU
worsen cardiovascular rnorlality, is not supporled by convincing data. The
future place of sU in clinical practice will depend on the outcome of
long-tenr studies like the UKPDS and on the developrnent of other
treatment strategies in NIDDM.
chapter 2 describes. using inh'averrous glucose tolerance tests, that the
acute administration of the potassium opener pinacidil, an antihypertensive
drLrg, has no srenificant efïect on insulin secretion. nor on qlucose
disappearance rate in hyperlensive patrents.
Sttntmru'y
Previous data indicated that pinacidil deteriorates glucose tolerance by
lowering plasma insulin levels, as measuredby ivGTT's in healthy subjects.
To confirm this, insulin release and insulin sensitivity were shrdied in l0
hypertensive patients and in l0 matched control subjects using the
hyperglycemic glucose clarnp technique, as the 'gold standard' for the
assessment of insulin secretion, yielding more precise results tlian the
ivGTT (chapter 3). In the hypertensive subjects fasting insulin levels were
significantly higher than in the control subjects, pointing to insulin
resistance. The K*[ATP] channel opener pinacidil drd not change insufin
release, neither in the hypertensives, nor in the controls. However, pinacidil
did enhance insulin sensitivity. This effect could be related to the
vasodilative action of pinacidil, enhancing glucose uptake in muscle. So,
based on the findings of our experiments, pinacidil l ias a profile, that makes
it an eligible antrhypertensive drug in patients with hyperlension with or
without NIDDM.
In chapter 4 four patients with hypokalernic periodic paralysis (HOPP),
a rare inherited disease, characterized by transient attacks of muscle
weakness, were studied with the hyperglycemic larnp technique. In HOPP,
abnormalities in insulin release and in K-[ATP] channels could be involved.
Insulin secretion and sensitivity appear to be normal in HOPP.
Hyperglycemia did not provoke paralytic attacks and did not result in a
decrease in muscle strength. Pinacidil may enhance muscle strength in those
HOPP patients, who have partial paralytic attacks. This has to be confinned
in a larger group of HOPP patients in different stages of the disease, who
take pinacidil for a longer period.
In NIDDM, first phase insulin secretion is dirninished or absent, while
second phase insulin release is markedly reduced. Sulphonylureas exefi
their effect by closure of the K-[ATP] channels of the pa:rcreatic B cell,
which results in insulin exocytosis. There may be differences in the vanous
SU in stiinulating first and/or second phase insulin release and with respect
to stimulation of rnsulin release at high blood glucose levels. In chapter 5
the influence of oral adrninistration of the SU glibenclarnide on first and
second phase insulin secretion was examined at submaximally (8 mrnol/l)
and maximally (>30 rnmol/l) stirnulating blood glucose levels in 12 healthy
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Glibenclamide increases second phase insulin secretion only at a
submaximally stirnulating blood glucose level without enhancement of first
phase insulin release, and has no additlve effect on insulin secretion at
rnaximally stimulating blood glucose levels. These findings are in
accordance with the theory glibenclamrde acts via a mechanism similar to
glucose, since a blood glucose level > 30 rnmol/l represents the maxirnally
stirnulating glucose concentration. Furthennore, glibenclamide did not
change insulin sensitivity in this acute experiment. Hyperglycemic clamp
studies in patients with non-insulin-dependent diabetes rnellitus could be
perforrned to confinn these findings in NIDDM.
Chapter 6 describes tudies with the SU gliclazide in 12 patients with
long-lasting NIDDM. Gliclazide has previonsly been shown to enhance first
phase insulin release in healthy subjects. After reaching stable euglycernia
(blood glucose 4.6 mmol/l) with the hyperinsulinernic euglycemic clamp
technique, the effect of 160 rng gliclazide on first and second phase insulin
secretion during a 4 hr hyperglycemic lamp (blood glucose 8 mmol/l) was
studied in a randomized, double blinded, cross-over study design. No
evidence of an effect of gliclazide on first phase insulin secretion was found
in these patients with long- standing NIDDM, who had an inconsiderable -
l5o% of norrnal - first phase. On the other hand, second phase insulin release
showed a marked and sustained increase during the last 3 hours of the
hyperglycemic clarnp. So, after gliclazide has closed the ATP-sensitive
potassium channel of tlie B cell, resulting in an influx of calciurn ions, the
cascade whrch results in first phase insulin release apparently is blocked,
whereas stimulation of second phase insulin release is intact.
In chapter 7 the suppression of plasma free fatty acids (FFA) and
triglycerides by acute hyperglycemia-induced hyperinsulinemia s well as
baseline plasma lipids, plasma LCAT and CETP activity were studied in
8 patients with essential hypertension and in 8 matched control subjects.
Essential hyperlension is associated wrth abnormalities in FFA and
triglyceride metabolism. During a 3 hr hyperglycemic lamp (blood glucose
l0 rnrnolil) plasma FFA and triglycerides decreased to a lesser extent and
remained higher in the hypertensive patients, despite sirnilar plasma insulin
levels. Baseline plasma FFA, total cholesterol and HDL cholesterol were
not different between the groups, but plasma triglycerides tended to be
Summarv
higher in the hypertensive patients. The plasma LCAT/CETP ratio was
higher in the hypertensive patients. So, in essential hypertension the action
of insulin on FFA metabolism is impaired, which is likely to contribute to
higher plasma triglycerides. In turn, higher triglycerides influence the HDL
lipid composition, either directly or via an effect on the plasma
LCAT/CETP rat io.
Final remarks
Potassium channel blocking agents (sulphonylureas) are widely used in the
treatment of type 2 diabetes mellitus. Recently, interest has grown in the
effects of SU on ATP-sensitive potassium channels of other organs, such
as the myocardial cell and the vascular cell. In this aspect, differences have
been found between the SU glibenclamide and glimepiride, glibenclamide
blocks vascular ATP-sensitive potassium channels, whereas glimepiride
does not have this property. Expenments with SU on myocardial cells
indicate that they rnay increase cardiac ischemia and infarct size by
inhibition of the reflectory vasodilation during cardiac oxygen depletion.
Other studies suggest a cardioprotective effect of SU on rhythm
disturbances of the heart, for example during myocardial infarction.
Outcomes of prospective clinical studies are needed to define the clinical
relevance of these in vitro findings. The recently cloned SU receptor (SUR)
and its isofonns in various organ cells could also be of great importance in
the understanding of the action of SU on different organs. Because the
majority of NIDDM patients use SU to treat their disease, it is important
that questions concerning possible cardiovascular effects of these drugs in
man will be answered in the near future.
